2023 World Conference on Lung Cancer (Posters)-EP13.05. Comparative Study of LCNEC and LCLC of the Lung Pathologically Diagnosed by Surgical Resection Specimens

EP13.05. Comparative Study of LCNEC and LCLC of the Lung Pathologically Diagnosed by Surgical Resection Specimens - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to compare the clinicopathological features and postoperative prognosis of patients with lung large-cell neuroendocrine carcinoma (LCNEC) and lung large-cell carcinoma (LCLC) diagnosed through surgical resection. A total of 81 patients, including 40 cases of LCLC and 41 cases of LCNEC, were included in the study. The baseline characteristics of the two groups were similar. The median disease-free survival (DFS) was not statistically different between the two groups, with the median DFS of the LCLC group being 19.47 months and the estimated median DFS of the LCNEC group being 29.40 months. The recurrence or metastasis rate was high within 5 months after surgery for both groups. The study also found that the level of serum CYFRA21-1 was higher in the LCLC group compared to the LCNEC group. However, there were no significant differences in the effect of adjuvant chemotherapy on DFS between the two groups. <br /><br />The findings of this study suggest that clinicopathological features of LCNEC and LCLC diagnosed through surgical resection are remarkably similar. Additionally, early recurrence or metastasis rates are high in both groups. The increase in serum CYFRA21-1 level can be helpful in distinguishing between the two types of cancers. Different factors were found to affect DFS in the two groups, but the effect of different adjuvant chemotherapy schemes on DFS was not significant in either group.

Asset Subtitle

Junxi Xu

Meta Tag

Speaker Junxi Xu

Topic SCLC & Neuroendocrine Tumors: NETs

Keywords

lung large-cell neuroendocrine carcinoma

lung large-cell carcinoma

clinicopathological features

postoperative prognosis

surgical resection

disease-free survival

recurrence rate

metastasis rate

serum CYFRA21-1 level

adjuvant chemotherapy